| [February 13, 2012] |
 |
Glancy Binkow & Goldberg LLP Announces Investigation of SeraCare Life Sciences, Inc.
LOS ANGELES --(Business Wire)--
Glancy Binkow & Goldberg LLP announces that it is investigating
potential claims against the Board of Directors of SeraCare Life
Sciences, Inc. ("SeraCare" or the "Company") (NASDAQ:SRLS) related to
the proposed acquisition of the Company by Linden Capital Partners. The
transaction is valued at approximately $82 million or $4.00 per share.
The investigation concerns whether the Board of Directors of SeraCare
breached their fiduciary duties to stockholders by failing to adequately
shop the Company before agreeing to enter into the propose transaction,
and whether the Company has disclosed all material information to
shareholders about the transaction. The Company has seen substantial
recent growth. Its share price has sky rocketed from $2.64 on October 4,
2011 to $3.58 on February 10, 2012. Further, at least one analyst has
set a target price for the Company's stock at $5.00.
If you are a shareholder of SeraCare, if you have information or would
like to learn more about these claims, or if you wish to discuss these
matters or have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact Louis
Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East,
Suite 2100, Los Angeles, CA (News - Alert) 90067, by telephone at (310) 201-9150 or
Toll Free at (888) 773-9224 or by email to shareholders@glancylaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To TMCnet.com's Homepage ]
|
TMCnet LOGIN
Webinars
